Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, July 19 '25)

Image
By G.M.

 


    Antiviral Res

  1. LEBEDIN M, Petrovsky N, Tabynov K, Tabynov K, et al
    SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody.
    Antiviral Res. 2025;241:106235.
    PubMed         Abstract available


    BMJ

  2. ARETOULI E, Malik M, Widmann C, Parker AM, et al
    Cognitive and mental health outcomes in long covid.
    BMJ. 2025;390:e081349.
    PubMed         Abstract available


    Clin Infect Dis

  3. SIZA C, Plucinski M, Lessa FC, Campelo E, et al
    Antibody Response in Healthcare Workers During the Severe Acute Respiratory Syndrome Coronavirus 2 Gamma Variant Outbreak in Manaus, Brazil.
    Clin Infect Dis. 2025 Jul 16:ciaf318. doi: 10.1093.
    PubMed         Abstract available

  4. SHOHAM S, Dioverti MV
    Combination Therapy for Protracted COVID-19: When More is More.
    Clin Infect Dis. 2025 Jul 16:ciaf384. doi: 10.1093.
    PubMed        

  5. LITTLE JS, Edelstein GE, Swank Z, Choudhary MC, et al
    Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic andiral Characteristics and Response to Dual and Extended Antiviral Therapy.
    Clin Infect Dis. 2025 Jul 16:ciaf383. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  6. GURLEY ES, Plowright RK
    A Roadmap of Primary Pandemic Prevention Through Spillover Investigation.
    Emerg Infect Dis. 2025;31.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  7. FORD JS, Wang RC, Stephenson B, Degesys NF, et al
    N95((R)) filtering facepiece respirator contamination with SARS-CoV-2 following reuse and extended use.
    Infect Control Hosp Epidemiol. 2025 Jul 14:1-6. doi: 10.1017/ice.2025.
    PubMed         Abstract available


    Intensive Care Med

  8. VAIDIE J, Demiselle J, Gabriel A, Guillon A, et al
    Effect of temporary suspension of chronic immunosuppressive drugs on day-90 mortality and ICU-acquired infections among critically Ill patients with solid organ transplant: a retrospective multicenter study.
    Intensive Care Med. 2025 Jul 16. doi: 10.1007/s00134-025-08024.
    PubMed         Abstract available


    J Infect

  9. MOOSA F, Kleynhans J, Makhathini L, du Plessis M, et al
    Bordetella pertussis infection and antibody dynamics in household cohorts in two South African communities, 2016 - 2018: findings from the PHIRST study.
    J Infect. 2025;91:106550.
    PubMed         Abstract available


    J Med Virol

  10. HUNG CT, Wang LM, Lee YJ, Suk CW, et al
    Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study.
    J Med Virol. 2025;97:e70494.
    PubMed         Abstract available

  11. KIM DH, Kim KS, Kim JH, Lim KB, et al
    Cross-Species Transmission of SARS-CoV-2 From Dogs to Hamsters and Pathological Changes in the Brain.
    J Med Virol. 2025;97:e70496.
    PubMed         Abstract available


    J Virol

  12. CARLOCK MA, Pierce SR, Ross TM
    Breadth of antibody activity elicited by an influenza B hemagglutinin vaccine is influenced by pre-existing immune responses to influenza B viruses.
    J Virol. 2025 Jul 15:e0070525. doi: 10.1128/jvi.00705.
    PubMed         Abstract available


    JAMA

  13. PRASAD V, Makary MA
    US FDA Safety Labeling Change for mRNA COVID-19 Vaccines.
    JAMA. 2025 Jul 14. doi: 10.1001/jama.2025.12675.
    PubMed        


    Lancet

  14. NEPOGODIEV D, Picciochi M, Ademuyiwa A, Adisa A, et al
    Surgical health policy 2025-35: strengthening essential services for tomorrow's needs.
    Lancet. 2025 Jul 14:S0140-6736(25)00985-7. doi: 10.1016/S0140-6736(25)00985.
    PubMed         Abstract available


    Lancet Infect Dis

  15. BROSH-NISSIMOV T
    Refining COVID-19 care for immunocompromised patients.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00316.
    PubMed        

  16. WEINSTEIN E, Paredes R, Gardner A, Almas M, et al
    Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00221.
    PubMed         Abstract available

  17. OGBUAGU O, Goldman JD, Gottlieb RL, Singh U, et al
    Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00238.
    PubMed         Abstract available

  18. FLAMANT A, Demirjian A, Lamagni T, Toubiana J, et al
    Invasive group A streptococcal infections: lessons learned from the 2022-23 upsurge.
    Lancet Infect Dis. 2025 Jul 9:S1473-3099(25)00343.
    PubMed         Abstract available


    Science

  19. COHEN J, Kaiser J
    NIH suspends alleged 'gain-of-function' studies.
    Science. 2025;389:223-224.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

Stability of #influenza viruses in the #milk of #cows and #sheep

By G.M.
Abstract In late 2023, H5N1 high pathogenicity avian influenza (HPAIV) started circulating in dairy cattle in the USA . High viral titres were detected in milk from infected cows , raising concerns about onwards human infections . Although pasteurisation was shown to effectively inactivate influenza viruses in milk, unpasteurised milk still poses a risk of infection, both from occupational exposure in dairies and from the consumption of raw milk. We therefore assessed how long influenza viruses could remain infectious for in milk without heat inactivation. We examined the stability of a panel of influenza viruses in milk , including a contemporary H5N1 HPAIV and a variety of other influenza A and D viruses. We incubated viruses in cows' milk under laboratory conditions : at room temperature to simulate exposure in dairies and at 4°C to simulate exposure to refrigerated raw milk. Following an isolated report of H5N1 viral RNA being detected in milk from a sheep in the UK , we also c...
Post a Comment
Read more »

#Evidence of #Viremia in Dairy #Cows Naturally Infected with #Influenza A {#H5N1} Virus, #California, #USA

By G.M.
Abstract We confirmed influenza A virus (IAV) by PCR in serum from 18 cows on 3 affected dairy farms in California, USA . Our findings indicate the presence of viremia and might help explain IAV transmission dynamics and shedding patterns in cows. An understanding of those dynamics could enable development of IAV mitigation strategies. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/7/25-0134_article ____
Post a Comment
Read more »